Stuttgart
20.12.24
08:11 Uhr
1,612 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Abera and Orexo partner for vaccine powder formulations | 1 | Pharmaceutical Technology | ||
| Di | Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology | 1 | Seeking Alpha | ||
| OREXO Aktie jetzt für 0€ handeln | |||||
| Di | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 325 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
| 02.12. | Orexo exits depression DTx alliance with GAIA | - | pharmaphorum | ||
| 02.12. | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 148 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
| 25.10. | Orexo initiates new study of OX640 in participants with allergic rhinitis | 247 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
| 24.10. | Orexo AB reports Q3 results | 1 | Seeking Alpha | ||
| 24.10. | Orexo Interim Report Q3 2024 | 331 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
| 04.10. | Orexo's Nomination Committee for the Annual General Meeting 2025 | 238 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
| 03.09. | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 270 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen | |
| 17.07. | Orexo AB GAAP EPS of -SEK1.04, revenue of SEK154M | 1 | Seeking Alpha | ||
| 17.07. | FDA issues CRL to Orexo's NDA for opioid overdose medication | 1 | Pharmaceutical Technology | ||
| 17.07. | Orexo Q2 2024 Interim Report | 342 | PR Newswire | UPPSALA, Sweden, July 17, 2024 /PRNewswire/ --
Making progress, while the OX124 review time extended
Q2 2024 highlights
Total net revenues of SEK 154.0 m (157.7)EBITDA of SEK... ► Artikel lesen | |
| 16.07. | Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose | 338 | PR Newswire | UPPSALA, Sweden, July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food... ► Artikel lesen | |
| 10.07. | Orexo AB's sustainability work ranked among top 5% by EcoVadis | 403 | PR Newswire | UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world's most trusted... ► Artikel lesen | |
| 08.07. | Orexo: invitation to presentation of the Q2 2024 Interim Report | 365 | PR Newswire | UPPSALA, Sweden, July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm... ► Artikel lesen | |
| 10.05. | Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm | 878 | PR Newswire | UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating... ► Artikel lesen | |
| 08.05. | Orexo Q1 2024 Interim Report | 396 | PR Newswire | UPPSALA, Sweden, May 8, 2024 /PRNewswire/ --
Starting 2024 with a positive EBITDA
Q1 2024 highlights
Total net revenues of SEK 139.3 m (158.8)EBITDA of SEK 15.9 m (-41.1)Net... ► Artikel lesen | |
| 26.04. | Report from Orexo AB's annual general meeting, 26 April 2024 | 298 | PR Newswire | UPPSALA, Sweden, April 26, 2024 /PRNewswire/ --
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance... ► Artikel lesen | |
| 17.04. | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | 302 | PR Newswire | UPPSALA, Sweden, April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another... ► Artikel lesen |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,100 | +0,49 % | Better Marijuana Stock: Aurora Cannabis or Tilray Brands? | ||
| ABBVIE | 169,00 | +0,33 % | AbbVie: Schon wieder - nächste Übernahme | Der Pharma-Riese AbbVie stärkt sein Immunologie-Portfolio. Für einen dreistelligen Millionen-Dollar-Betrag sichern sich die Amerikaner die Dienste des Biotech-Unternehmens Nimble Therapeutics. Das Übernahmeziel... ► Artikel lesen | |
| TILRAY BRANDS | 1,219 | +2,05 % | Ausverkauf und dann Comeback?: Darum sind Tilray, Canopy & Co. potenzielle Highflyer in 2025. Und darum nicht | © Foto: adobe.stock.comDas Jahresende bringt für den Cannabis-Sektor noch einmal Turbulenzen mit sich. Das Jahr endet, wie es verlief; könnte man salopp formulieren. Zudem dürfte Tilray, Canopy & Co.... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,44 | -0,87 % | Bristol Myers Squibb und der große Hoffnungsträger - Immatics-Deal vor dem Aus | Vor knapp einem Jahr sorgte Bristol Myers Squibb mit einem Übernahme-Doppelschlag für Furore. Um Weihnachten herum kündigten die Amerikaner die Akquisitionen von Karuna Therapeutics und RayzeBio an.... ► Artikel lesen | |
| TEVA | 20,900 | -1,42 % | Teva-Aktie schießt hoch: "Beispiellose Ergebnisse" - neue Hoffnung für Millionen | Laut "Leben mit CED" betreffen die chronisch-entzündlichen Darmerkrankungen Morbus Crohn oder Colitis ulcerosa weltweit etwa sechs bis acht Millionen Menschen. Ein großer, nachhaltiger therapeutischer... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 379,85 | -0,25 % | Datenflut bei Biotechs und Pharmas: Vertex rauscht nach unten, Zittern bei Novo Nordisk | Was Daten bei einer auch großen Aktie auslösen können, verdeutlichte heute Vertex. Die Aktie verliert aktuell mehr als zwölf Prozent, nachdem die Studienergebnisse zu einem neuartigen Schmerzmedikament... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,004 | +2,67 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 71,56 | -0,21 % | Jim Cramer: Is Edwards Lifesciences (EW) Poised for a Comeback? | ||
| BAUSCH HEALTH | 7,140 | -0,13 % | Bausch Health Companies Inc.: Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb | LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through... ► Artikel lesen | |
| BIONANO GENOMICS | 0,201 | -0,64 % | Bionano Genomics-Aktie erreicht 52-Wochen-Tief bei 0,2 US-Dollar | ||
| ASTRIA THERAPEUTICS | 9,560 | +1,16 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| AMARIN | 0,450 | -1,75 % | Amarin-Aktie erreicht 52-Wochen-Tief bei 0,45 US-Dollar | ||
| OPKO HEALTH | 1,477 | -0,28 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| JAGUAR HEALTH | 0,929 | +6,44 % | Jaguar Health, Inc.: Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications | Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indicationsThe import was conducted in collaboration with the government of... ► Artikel lesen | |
| ENDO | - | - | Endo, Inc.: Endo Announces Publication of Peyronie's Disease Self-Assessment Screening App Article in Peer-Reviewed Translational Andrology and Urology | MALVERN, Pa., Dec. 16, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the publication of the Peyronie's disease (PD) self-assessment screening app by the peer-reviewed journal... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.
